Imagen Biotech has secured up to $40 million in Series A financing from SV Life Sciences, Novo Ventures, and Fidelity Biosciences to pursue the identification and development of breakthrough treatments for blinding diseases with high unmet medical needs, including dry age-related macular degeneration. Matthew Feinsod, MD, an ophthalmologist who was formerly at Eyetech Pharmaceuticals and a medical officer in the FDA's Ophthalmology Division, will lead these efforts as chief medical officer for Imagen. Additional terms will not be disclosed.

"With capital commitment in place, Imagen can focus 100% of our energy and resources on bringing the best therapies to patients. We are grateful to our investor partners for this opportunity," Dr. Feinsod notes.